Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026
Portfolio Pulse from
Moleculin Biotech, Inc. has received US IRB approval for its Phase 3 MIRACLE trial of Annamycin for AML treatment, with dosing to begin in Q1 2025. Preliminary results show promising efficacy, and the company anticipates accelerated NDA processes by 2027.
January 08, 2025 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Moleculin Biotech has received approval for its Phase 3 MIRACLE trial for Annamycin, showing promising preliminary results in AML treatment. The trial is set to begin dosing in Q1 2025, with potential accelerated NDA processes by 2027.
The approval for the Phase 3 trial and promising preliminary results suggest a positive outlook for Moleculin's Annamycin, potentially leading to accelerated NDA processes. This is likely to boost investor confidence and positively impact MBRX's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100